Roar Adelsten
Owns 64.4 percent (privately and via companies). Founder and business developer within the Auxesis group since 2014.
Financial information
Welcome to Auxesis Pharma’s financial section. Here you will find financial information, press releases and information about the ownership structure. Auxesis Pharma develops differentiated drug assets focused on major medical needs in wound care and specialized dermatology.
2016
Founded
800
Shareholders
1(+3)
Patents
Global market potential
Skin pain and irritation category (OTC human)
- The global market for dermal pain relief is expected to reach USD 12.2 billion in 2027, with a growth rate of 5.2% CAGR (2020–2027).
- North America and Europe account for 68% of the global market.
- Asia-Pacific is expected to have the strongest growth rate during 2020–2027 at 6.5% CAGR.
* The distribution in the chart shows regional market share (example data).
Capital
Financing strategy
Current round: VC Growth / Late Seed – Series A Bridge
Use of proceeds
- Clinical development
- Regulatory preparation EU / USA
- Manufacturing scale-up
- Business development and partnerships
Vision
Target state
- Value creation through clinical milestones
- Opportunity for strategic licensing or M&A
- Clear path toward a commercial specialty pharma model
A solid ownership structure
Other owners
Other owners collectively hold 35.6 percent and are mainly private individuals and small companies.
Shareholders
Auxesis has approximately 800 shareholders. The source for shareholdings is Euroclear Sweden, which maintains the share register. Figures as of 2025-12-31.
Overview
- Clear regulatory pathway in major markets
- Strong IP strategy around formulation and indication expansion
- Capital-efficient development model
- Multiple strategic routes through partnerships or licensing
Ownership structure
Founders & management65%
Early owners7%
Strategic / industrial0%
Incentive program (ESOP)0%
Free float / others28%
Management team
Experienced leaders with deep expertise in medtech, pharmaceuticals and business development
Peter Åberg
CEO, Drug Development and Sustainability
Peter Åberg leads Auxesis’ strategic development with exceptional expertise in medtech and pharmaceuticals.
Expertise and background
- •CEO and sustainability director in medtech
- •Toxicology and drug safety
- •International leadership experience
Contribution: Drives Auxesis strategically toward sustainable global growth.
Roar Adelsten
Founder and Board Member
Visionary founder with nearly 30 years of experience in the pharmaceutical industry.
Expertise and background
- •Pfizer AS – medical consultant
- •International experience
- •Product development in orthopedics
Contribution: Ensures long-term strategy and innovation.
Lars Larsson
Finance
Lars Larsson is responsible for Auxesis’ finance and financial strategy. With solid experience in financial management and business development, he ensures the company’s financial stability and growth.
Expertise and background
- •Extensive experience in financial leadership and management control
- •Specialist in strategic financial planning and budgeting
- •Expertise in investor relations and capital markets
- •Experience from finance functions within the life science sector
Contribution: Ensures financial stability and drives financial growth that enables Auxesis’ continued expansion and innovation.
A well-balanced board and management team
Auxesis Pharma has a well-balanced board and management team representing diverse areas of expertise
Auxesis Pharma Board of Directors
Roar Adelsten
Deputy CEO and Board Member
Magnus Larsson
Chair of the Board
Rune Nordström
Board Member
Charlotta Larsson
Board Member
Auxesis Pharma Management Team
Peter Åberg
CEO, Drug Development and Sustainability
Roar Adelsten
Deputy CEO
Lars Larsson
Finance
Financial calendar
Key dates for financial reports, annual general meetings and other investor events.
Upcoming events
Ongoing offering
The ongoing offering can be subscribed to until 2026-02-13.
Upcoming offering
The upcoming offering can be subscribed to from 2026-02-14.
AGM 2026
Publication of the AGM for the full year 2026.
Financial reports
Annual Report 2024
June 2025
Annual Report 2023
June 2023
Contact IR
Do you have questions about the company or want to book a meeting with our IR representative?
Investor Relations
+46 (0)8-771 43 00